Core Viewpoint - Autolus Therapeutics plc is set to release its first quarter 2025 financial results and operational highlights on May 8, 2025, before the US markets open [1]. Group 1: Financial Results Announcement - The company will host a conference call and webcast at 8:30 am EDT/13:30 pm BST to discuss the financial results and provide a general business update [2]. - Participants are required to pre-register to receive dial-in numbers and a personal PIN for accessing the conference call [2]. Group 2: Company Overview - Autolus Therapeutics plc is an early commercial stage biopharmaceutical company focused on developing next-generation T cell therapies for cancer and autoimmune diseases [3]. - The company utilizes proprietary and modular T cell programming technologies to create targeted and highly active T cell therapies [3]. - Autolus has an FDA-approved product, AUCATZYL, and a pipeline of candidates for treating hematological malignancies, solid tumors, and autoimmune diseases [3].

LONDON, April 02, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the Company will participate in the 24th Annual Needham Virtual Healthcare Conference. Autolus Chief Executive Officer Dr. Christian Itin will present in a Fireside Chat on Wednesday, April 9, 2025 at 9:30am EDT / 14:30pm BST. A webcast of the fireside chat will be available ...

LONDON, April 01, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announced that the Company will host an R&D investor event on Wednesday, April 23, 2025 at 8:30am EDT / 13:30pm BST. The live event will be held in New York City. To inquire about in-person attendance please email: susan@sanoonan.com. Amanda Cray +1 617-967-0207 a.cray@autolus.com About Au ...

Autolus will present an update on clinical pipeline programs, including plans to expand the obe-cel opportunity. The Company expects to report initial data in six patients from the ongoing CARLYSLE Phase 1 trial in systemic lupus erythematosus (SLE), announce development plans for expansion in autoimmune diseases, and provide a brief update of the ongoing commercial launch of AUCATZYL®. LONDON, April 01, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (NASDAQ:AUTL), an early commercial-stage biopharmaceut ...

Table of contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from to Commission file number: 001-38547 Autolus Therapeutics plc (Exact name of Registrant as specified in its charter) England and Wales Not applicable (State ...

Autolus Therapeutics plc (NASDAQ:AUTL) Q4 2024 Earnings Conference Call March 20, 2025 8:30 AM ET Company Participants Amanda Cray - IR Christian Itin - CEO Rob Dolski - CFO Conference Call Participants James Shin - Deutsche Bank Rajan Sharma - Goldman Sachs Asthika Goonewardene - Truist Matt Phipps - William Blair Gil Blum - Needham & Company Kelly Shi - Jefferies Yanan Zhu - Wells Fargo Jacob Mekhael - KBC Securities Simon Baker - Redburn Atlantic Operator Hello, ladies and gentlemen, and welcome to the A ...

Q4 2024 Financial Results and Business Updates 20 March 2025 For Investor communication only. Not for use in product promotion. Not for further distribution. Autolus.com Disclaimer These slides contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as "may," "will," "could," "expects," "plans," "anti ...

Financial Results Announcement - Autolus Therapeutics plc announced its financial results for the year ended December 31, 2024, during a conference call on March 20, 2025[5] - The press release detailing the financial results is included as Exhibit 99.1[9] Corporate Presentation - The company provided an updated corporate presentation alongside the financial results, which is available as Exhibit 99.2[7]

Core Insights - Autolus Therapeutics achieved significant milestones in 2024, including FDA approval and commercial launch of AUCATZYL, a CAR T therapy for adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) [2][5] - The company is focused on expanding its commercial launch and advancing its clinical pipeline in 2025, with plans to enter new markets and invest in the obe-cel opportunity [2][4] Financial Performance - As of December 31, 2024, cash, cash equivalents, and marketable securities totaled $588.0 million, up from $239.6 million in 2023, primarily due to a strategic collaboration with BioNTech [8] - The net loss for the year ended December 31, 2024, was $220.7 million, compared to a loss of $208.4 million in 2023, with a basic and diluted net loss per share of $(0.86) [12][18] - Research and development expenses increased to $138.4 million from $130.5 million in 2023, while selling, general, and administrative expenses rose significantly to $101.1 million from $46.7 million [10][11] Product Development and Regulatory Updates - AUCATZYL was approved by the FDA on November 8, 2024, and is progressing well in the U.S. commercial launch with 33 authorized treatment centers as of March 19, 2025 [4][5] - The company expects marketing authorizations for obe-cel from the MHRA and EMA in the second half of 2025 [4][6] - Initial data from the Phase 1 trial in systemic lupus erythematosus (SLE) will be presented at an R&D event on April 23, 2025 [7][20] Clinical Trials and Pipeline - The pivotal Phase 1b/2 FELIX clinical trial of obe-cel demonstrated high rates of durable responses with low incidence of severe immune-related toxicity [5][9] - Autolus is also advancing early-stage pipeline programs, including AUTO8 and AUTO6NG, with updates planned for the upcoming R&D event [10][20] Market Access and Coverage - Patient access to AUCATZYL is strong, with coverage secured for over 85% of total U.S. medical lives, and the company aims to authorize 60 treatment centers by the end of 2025 [5][8] - The National Comprehensive Cancer Network (NCCN) has included AUCATZYL in its Clinical Practice Guidelines for the treatment of adult patients with relapsed/refractory B-ALL [5]

Core Insights - Autolus Therapeutics plc is set to release its fourth quarter and full year 2024 financial results on March 20, 2025, before the US markets open [1] - A conference call and webcast will be held on the same day at 8:30 am EDT/12:30 pm GMT to discuss the financial results and provide a business update [2] Company Overview - Autolus Therapeutics plc is an early commercial stage biopharmaceutical company focused on developing next-generation T cell therapies for cancer and autoimmune diseases [3] - The company utilizes proprietary T cell programming technologies to create targeted and controlled T cell therapies aimed at effectively recognizing and eliminating target cells [3] - Autolus has an FDA-approved product, AUCATZYL, and is developing a pipeline of candidates for treating hematological malignancies, solid tumors, and autoimmune diseases [3]